MSD Bets $400 Million on a Preclinical Molecule as October Earnings Loom

MSD licensed SciBrunch's preclinical KRAS G12D drug SPR2015 for up to $2.13B, booking a $400M charge before its October 29 earnings call.

MSD has committed a hefty upfront sum to secure a drug candidate that has yet to reach human trials. On Monday, the company finalized a worldwide licensing agreement with SciBrunch Therapeutics covering SPR2015, an oral compound targeting the KRAS G12D mutation. The deal grants MSD global rights to develop, manufacture, and commercialize the molecule, with $400 million paid upfront and milestone payments that could push the total value as high as $2.13 billion.

The transaction closed immediately upon signing, and it lands just as investors are turning their attention to the company's next scheduled appearance on the capital markets calendar. MSD confirmed yesterday that it will hold its third-quarter 2026 earnings call on October 29 at 9:00 a.m. ET.

That proximity matters. The upfront payment will hit the upcoming quarterly result as a $400 million pre-tax charge, meaning the licensing move and the earnings report are now inseparable in the minds of shareholders.

A preclinical gamble with an immediate balance-sheet cost

The central tension is straightforward: how much near-term financial strain is MSD absorbing to strengthen a pipeline whose payoff sits years away? Writing a $400 million check for an asset still in preclinical development is a substantial outlay, and market participants will be watching closely to see how management balances pipeline expansion against capital discipline.

Whether the upfront charge meaningfully narrows operating flexibility in the current fiscal year is one question. Another is where future licensing deals rank against existing research spending in management's priorities. Entering new drug classes also demands a hard look at development capacity — investors must judge whether broader research activity justifies the value it is meant to create, or whether it dilutes return expectations in the short run.

Clinical momentum offers a counterweight

Not everything rests on an unproven molecule. MSD's Phase 2b study MK-7240-012 showed that Tulisokibart met its primary endpoint in patients with moderate-to-severe hidradenitis suppurativa, a result the company frames as groundwork for Phase 3 development. In the trial, 72% of patients in the high-dose arm and 64% on the middle dose achieved a HiSCR50 response, against 35% on placebo.

The market, however, greeted Wednesday's data release with restraint. Media reports put the stock down 2.66% that day. Shares closed yesterday at EUR 127.92, roughly 5.2% below their 52-week high of EUR 134.88 — a pullback that comes after a 41% gain since the start of the year, leaving investors to weigh how durable that re-rating really is.

Skepticism centers on the commercial profile of Tulisokibart and how it differentiates from rivals, as well as the broader need to convert research spending into high-margin revenue without delay.

Regulatory wins keep the bull case alive

Supporting the optimistic reading, Scotiabank raised its price target on Tuesday from $155 to $180 while keeping an "Outperform" rating, arguing that both marketed products and the development pipeline remain undervalued by the market.

The approval record backs that view to some extent. On September 25, the FDA cleared the combination of Welireg and Lenvima for certain adults with advanced clear cell renal cell carcinoma following prior PD-1 or PD-L1 therapy. Three days earlier, on September 22, the agency approved a label update for Winrevair based on Phase 3 data from the HYPERION study, reinforcing its use in newly diagnosed pulmonary arterial hypertension.

In Europe, the CHMP issued a positive recommendation on September 18 for Keytruda combined with Padcev in muscle-invasive bladder cancer, while Japan on September 21 approved subcutaneous administration of Keytruda Qlex across all Keytruda indications cleared in the country. Should this run of market openings continue, the stock could resume its upward trajectory.

Late-stage setbacks temper the risk profile

The bearish case draws on the very real dangers of clinical failure and regulatory roadblocks. On September 25, MSD and Daiichi Sankyo voluntarily withdrew their application for Ifinatamab deruxtecan in previously treated advanced small cell lung cancer after talks with the FDA showed the submitted data fell short of accelerated approval requirements. The Phase 3 IDeate-Lung02 trial continues, but the retreat represents a painful delay.

Data reported September 24 from the Phase 2b/3 BRUNELLO study of Remigromig in diabetic macular edema add to the caution. The drug proved non-inferior to Ranibizumab on visual acuity change at 52 weeks, yet proliferative diabetic retinopathies, vitreous hemorrhages, and treatment-related discontinuations occurred more frequently with Remigromig. If regulators demand further hurdles, or if future Phase 3 programs such as Tulisokibart signal additional capital needs, the valuation premium built up over recent months could erode.

Chart levels and the October catalyst

The stock is trading at EUR 127.70 today, caught between medium-term consolidation and its broader trend. As long as it holds above the 50-day moving average of EUR 123.77, the underlying structure remains constructive; a sustained break below that level would open the door to an extension of the consolidation toward the 200-day average of EUR 106.08.

Everything now funnels toward October 29. When management takes questions from 9:00 a.m. ET, it will have to detail the $400 million charge, lay out the Phase 3 timeline for Tulisokibart, and clarify the regulatory status of Remigromig. Until then, the shares are likely to trade on how the market reads the pipeline's risks — and on whether the SciBrunch deal is seen as a deliberate bet on oncology's future or an expensive leap of faith.